← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Us Worldmeds, Llc
Louisville, KY
$27,189,670
Total funding
3
Grants
Funding over time
peak $7.4M · FY2011–20$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$27,189,670 · 3
By mechanism
U01$23,389,670 · 2
R01$3,800,000 · 1
Investigators at Us Worldmeds, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Phase 3, Double-Blind Efficacy, Safety and Dose-Response Study of Lofexidine (S$5,982,000
U01 · FY2012 · DA
A Phase 3, Double-Blind Efficacy, Safety and Dose-Response Study of Lofexidine (S$5,967,600
U01 · FY2014 · DA
A Phase 3, Double-Blind Efficacy, Safety and Dose-Response Study of Lofexidine (S$5,544,365
U01 · FY2013 · DA
Accelerated Development of Lofexidine for Neonatal Opioid Withdrawal Syndrome$2,330,000
R01 · FY2019 · DA
NDA-Enabling Phase I Lofexidine Program$1,438,532
U01 · FY2014 · DA
NDA-Enabling Phase I Lofexidine Program$1,107,186
U01 · FY2013 · DA
NDA-Enabling Phase I Lofexidine Program$999,244
U01 · FY2011 · DA
NDA-Enabling Phase I Lofexidine Program$976,880
U01 · FY2012 · DA
NDA-Enabling Lofexidine Program - Final Regulatory Clinical Requirements for NDA Submission$813,971
U01 · FY2016 · DA
Accelerated Development of Lofexidine for Neonatal Opioid Withdrawal Syndrome$800,000
R01 · FY2020 · DA
Accelerated Development of Lofexidine for Neonatal Opioid Withdrawal Syndrome$670,000
R01 · FY2018 · DA
NDA-Enabling Phase I Lofexidine Program$468,517
U01 · FY2012 · DA
NDA-Enabling Phase I Lofexidine Program$91,375
U01 · FY2013 · DA